GPhC registered|Tracked Delivery
Mounjaro (Tirzepatide)
Active ingredient
Tirzepatide
Formulation
Subcutaneous pen injection
Class
Dual GLP-1 / GIP receptor agonist
Manufacturer
Eli Lilly
“Every Mounjaro prescription is reviewed personally. We check suitability, interactions, and whether it is the right clinical choice.”
— Younes Mekhalfia, GPhC-registered pharmacist

Mounjaro

Tirzepatide

A once-weekly dual-agonist (GLP-1 and GIP) injection used as part of a UK pharmacist-led weight management programme, prescribed after clinical review.

£149/ month

2.5mg · Starter · Subscribe & Save · £169 without subscription

Final pricing confirmed at assessment.

Select strength

Your prescriber confirms your Mounjaro dose at assessment.

  • Once-weekly pen injection
  • Dual hormone action (GLP-1 + GIP)
  • Refill request reviewed before every supply
  • Free sharps bin and injection guide included
Check eligibility

Free consultation · You’re only charged if treatment is approved

  • GPhC-registered pharmacy
  • UK Licensed Medication
  • Discreet packaging

Transparent pricing

Dose Pricing

Prices are shown per month. Subscribe & Save reduces the monthly cost while keeping every treatment decision under prescriber review.

No automatic dose changes
StrengthFlexibleSubscribe & Save
2.5mg£169£149
5mg£199£179
7.5mg£259£239
10mg£289£269
12.5mg£309£289
15mg£319£299

Dose changes only proceed after prescriber review of your progress, tolerance, side effects, and updated clinical information. Your treatment plan proceeds only when clinically approved.

How it works

How Mounjaro works in the body

  1. Regulates appetite

    Tirzepatide activates both GLP-1 and GIP receptors in the brain, reducing hunger signals and the sensation of 'food noise' that drives non-hungry eating.

  2. Slows gastric emptying

    Food stays in the stomach longer, so you feel fuller after smaller portions and blood sugar rises more gradually after meals.

  3. Improves insulin response

    The dual action supports better glycaemic control — one of the reasons tirzepatide was originally licensed in the UK for type 2 diabetes before weight management.

Clinical evidence

What the trial data shows

Peer-reviewed evidence for Mounjaro, cited and attributed — not reframed as a personal promise.

Randomised controlled trial

SURMOUNT-1

Jastreboff AM et al., NEJM 2022;387:205–216

Participants
2,539
Duration
72 weeks
Comparator
vs. placebo, alongside lifestyle intervention

At the highest dose (15 mg), participants lost an average of ~22.5% of baseline body weight versus ~3% on placebo. Trial participants had BMI ≥ 30, or ≥ 27 with a weight-related comorbidity.

Read the full paper

Trial results do not predict individual outcomes. Your pharmacist will discuss realistic expectations during consultation.

Dosing

Typical dosing schedule

Doses escalate gradually under pharmacist supervision to support tolerability. Your exact plan is set during your consultation.

Typical Mounjaro dose escalation schedule
WeekNotes
Weeks 1–4

2.5 mg

Starter dose — primarily for tolerance, not full therapeutic effect

Weeks 5–8

5 mg

First therapeutic maintenance dose

Weeks 9–12

7.5 mg

Optional step — many patients maintain here

Weeks 13–16

10 mg

Higher maintenance dose if tolerated and clinically indicated

Weeks 17+

12.5 – 15 mg

Highest maintenance doses — only used if lower doses are well tolerated and progress has stalled

Safety profile

Possible side effects

Grouped by frequency. Your pharmacist will review these with you in detail before you start.

Common
  • Nausea (most common in first 2–4 weeks)
  • Diarrhoea
  • Constipation
  • Reduced appetite / early satiety
  • Indigestion or heartburn
  • Injection-site reactions (redness, itch)
Uncommon
  • Vomiting
  • Abdominal pain
  • Dizziness
  • Gallbladder disease
  • Hair thinning (associated with rapid weight loss, not the drug itself)
Rare
  • Acute pancreatitis — seek urgent medical advice for severe abdominal pain
  • Severe allergic reaction
  • Hypoglycaemia (mainly if combined with insulin or sulfonylureas)

Not a complete list. Read the Patient Information Leaflet supplied with your medication. Report any suspected side effects to the MHRA Yellow Card scheme.

Eligibility

Is Mounjaro right for you?

Usually suitable for

  • Adults (18+) with BMI ≥ 30, or ≥ 27 with a weight-related condition
  • Patients who have attempted lifestyle-led weight management without sustained effect
  • Patients able to administer a once-weekly subcutaneous injection
  • Patients who can attend follow-up pharmacist reviews as part of the programme

Not suitable if you are / have

  • Pregnancy, planning pregnancy, or breastfeeding
  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome
  • Active severe gastrointestinal disease (e.g. gastroparesis, severe IBD)
  • History of acute pancreatitis
  • Type 1 diabetes (off-label for weight management)
  • Age under 18 years

This is a summary, not a complete assessment. A pharmacist reviews your full health history during consultation before any prescription is issued.

What’s included

Everything in your welcome kit

  • 01Mounjaro KwikPen (one month supply)
  • 02BD Ultra-Fine pen needles (4 mm)
  • 03Yellow sharps bin — first bin free, replacement free on request
  • 04Injection technique guide + cold-chain handling card
  • 05Direct pharmacist chat through your dashboard
Younes Mekhalfia - independent prescribing pharmacist
Independent Prescribing Pharmacist

Dispensed & Checked by Us

Unlike other online services, we don’t outsource your care. Every prescription is reviewed, dispensed, and packed by our UK-based clinical team. You’re not just a number - you’re a patient we’re committed to supporting.

“Each consultation is reviewed by a qualified prescriber within their clinical scope before any prescription treatment is supplied.”

— Younes Mekhalfia, Independent Prescribing Pharmacist

Every order

Clinical Review

In-house

UK Dispensing

Individual

Clinical Support

Real humans

Support

Everything you need to know about Mounjaro

Find answers about treatment, safety and the service journey.

How is Mounjaro different from Wegovy?

Mounjaro (tirzepatide) is a dual-agonist targeting two hormones — GLP-1 and GIP — whereas Wegovy (semaglutide) targets GLP-1 alone. In their respective pivotal trials (SURMOUNT-1 for tirzepatide; STEP-1 for semaglutide) the tirzepatide trial reported a larger average weight reduction over 68–72 weeks, but these were separate studies with different populations, so they are not strictly comparable. The best treatment for any individual depends on clinical history, tolerability, and pharmacist judgement.

What is the active ingredient in Mounjaro?

The active ingredient is Tirzepatide, a dual GLP-1 and GIP receptor agonist that regulates appetite and blood sugar.

What does the clinical trial data show?

In the SURMOUNT-1 randomised controlled trial (Jastreboff et al., New England Journal of Medicine, 2022), participants on the highest doses of tirzepatide lost an average of 20–22.5% of baseline body weight over 72 weeks versus roughly 3% on placebo. Trial results do not predict individual outcomes — your pharmacist will discuss realistic expectations as part of your consultation, taking into account your starting weight, health profile, and lifestyle.

Can Mounjaro be considered if semaglutide hasn't worked?

If a semaglutide-based treatment has not produced sustained progress, clinicians sometimes consider switching to tirzepatide because the additional GIP receptor activity acts on fat metabolism through a different pathway. Whether a switch is appropriate is always an individual clinical call made by your pharmacist on consultation — not a guaranteed next step.

How quickly does it start working?

Many patients report reduced appetite within the first 24–48 hours of treatment. Clinical response is tracked over weeks rather than days, and your pharmacist will discuss realistic timelines and what to expect during your consultation.

Is Mounjaro insulin?

No, it is not insulin. It mimics natural gut hormones that regulate blood sugar and appetite. It works differently from insulin and is not a replacement for it.

Does it slow down my metabolism?

No, it actually helps regulate metabolic function. However, it does slow down "gastric emptying," meaning food stays in your stomach longer, keeping you full and satisfied.

How often do I inject Mounjaro?

Once a week, on the same day each week. You can choose any day that suits your routine, and inject at any time of day.

What if I miss a dose?

If it is within 4 days of your scheduled dose, take it immediately. If more than 4 days have passed, skip it and wait for your next scheduled day. Never double up on doses.

Does the KwikPen come with needles?

Caremacy supplies high-quality needles with every order, but the pen itself does not have a needle attached until you screw one on before each injection.

How many doses are in one pen?

The UK Mounjaro KwikPen contains 4 weekly doses. One pen lasts 4 weeks (one month of treatment).

What are the dosage steps?

You start at 2.5mg for 4 weeks, then move to 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg. Each dose increase happens every 4 weeks based on your response and tolerance.

Do I have to go up to 15mg?

No. Many patients find a "sweet spot" at 5mg or 7.5mg and stay there for months. We only increase the dose if your weight loss stalls and you're tolerating the medication well.

Where is the best place to inject?

The stomach (abdomen) is most common, but the thigh or upper arm are also effective. Rotate your injection site weekly to prevent skin irritation.

Does the injection hurt?

The needle is extremely fine (4mm). Most patients describe it as a tiny scratch or feel nothing at all. It's much easier than most people expect.

Still have questions? Our pharmacist team is here to help.

Contact us

Your health shouldn’t wait.

Free consultation, pharmacist-reviewed, discreet delivery.

Start your consultation